Milovanov Iu S, Milovanova L Iu
Ter Arkh. 2012;84(6):48-52.
Comparison of efficacy of 12-month treatment of anemia in patients with chronic kidney disease (CKD) of stage III - IV with a long-acting drug darbepoetin alpha - aranesp and short-acting drug erythropoietin beta - recormon.
A total of 44 patients with CKD of stage III-IVwere divided into two groups. Of them, 24 had chronic glomerulonephritis and 20 had tubulointerstitial nephritis with verified nephrogenic anemia. Group 1 consisted of 22 patients given long-acting erythropoetin (darbepoetin alpha) in an initial dose 0,75 mcg/kg each 2 weeks subcutaneously. Group 2 consisted of 22 patients matched by age, gender, severity of anemia and renal failure with group 1 patients given short-acting erythropoietin (erythropoietin beta) in an initial 20 IU 3 times a week subcutaneous, for 12 months. In the phase of anemia correction and supporting therapy the levels of packed red blood cells, Hb, free serum ferrum, ferritin, percentage of iron in transfusion, serum albumin in blood serum, creatinin, glomerular filtration rate were examined monthly. The patients themselves daily measured blood pressure, diuresis, body mass.
The target level of Hb 110-120 g/l was achieved faster in group 2 than in group 1 (3 and 4 months, respectively). p < 0.05). In the phase of supporting a target Hb level, on the opposite, darbepoetin alpha provided more stable hemopoetin effect than erythropoietin beta, darbepoetin alpha median dose being constant in the course of the study.
比较长效药物阿法达贝泊汀（Aranesp）和短效药物β-促红细胞生成素（Recormon）对III - IV期慢性肾脏病（CKD）患者进行12个月贫血治疗的疗效。
总共44例III - IV期CKD患者被分为两组。其中，24例患有慢性肾小球肾炎，20例患有经证实的肾性贫血的肾小管间质性肾炎。第1组由22例患者组成，给予长效促红细胞生成素（阿法达贝泊汀），初始剂量为每2周皮下注射0.75 mcg/kg。第2组由22例患者组成，在年龄、性别、贫血严重程度和肾衰竭方面与第1组患者相匹配，给予短效促红细胞生成素（β-促红细胞生成素），初始剂量为每周皮下注射3次，每次20 IU，持续12个月。在贫血纠正和支持治疗阶段，每月检查红细胞压积、血红蛋白、血清游离铁、铁蛋白、输血中铁的百分比、血清白蛋白、肌酐、肾小球滤过率水平。患者自己每天测量血压、尿量、体重。
第2组比第1组更快达到血红蛋白目标水平110 - 120 g/l（分别为3个月和4个月，p < 0.05）。相反，在维持目标血红蛋白水平阶段，阿法达贝泊汀比β-促红细胞生成素提供更稳定的造血效果，在研究过程中阿法达贝泊汀的中位剂量保持恒定。
